Genetics and iron in the systems biology of Parkinson's disease and some related disorders

Neurochemistry International

Volumn 62, Issue 5, 2013, Pages 637-652

  Funke, Claudia ^a   Schneider, Susanne A ^b,c   Berg, Daniela ^a,d   Kell, Douglas B ^e  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

GWAS; Holistic analysis; Iron; PARK genes; Parkinson's disease; Systems biology

Indexed keywords

ALPHA SYNUCLEIN; CERAMIDE; DJ 1 PROTEIN; GLUCOSYLCERAMIDASE; HYDROXYL RADICAL; INITIATION FACTOR 4G; IRON; LEUCINE RICH REPEAT KINASE 2; PARKIN; PHOSPHOLIPASE A2; SERINE PROTEINASE OMI; TYROSINE KINASE RECEPTOR; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN THIOLESTERASE;

APOPTOSIS; ATP13A2 GENE; CELL DEATH; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; FBXO7 GENE; GENE; GENETIC ASSOCIATION; GENETICS; HUMAN; IRON METABOLISM; KUFOR RAKEB SYNDROME; LEWY BODY; LYSOSOME; MITOCHONDRIAL RESPIRATION; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PLA2G6 ASSOCIATED NEURODEGENERATION; PLA2G6 GENE; POSITIVE FEEDBACK; PRIORITY JOURNAL; REVIEW; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA; SYSTEMS BIOLOGY;

BIOCATALYSIS; BRAIN; CELL DEATH; HUMANS; IRON; ORGANELLES; PARKINSON DISEASE; SYSTEMS BIOLOGY;

EID: 84875719721     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2012.11.015     Document Type: Review

References (366)

1. V. Adam-Vizi Production of reactive oxygen species in brain mitochondria: contribution by electron transport chain and non-electron transport chain sources Antioxid. Redox Signal. 7 2005 1140 1149
2. V. Adam-Vizi, and C. Chinopoulos Bioenergetics and the formation of mitochondrial reactive oxygen species Trends Pharmacol. Sci. 27 2006 639 645
3. P.A. Adlard, R.A. Cherny, D.I. Finkelstein, E. Gautier, E. Robb, and M. Cortes Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta Neuron 59 2008 43 55
4. J. Aharon-Peretz, S. Badarny, H. Rosenbaum, and R. Gershoni-Baruch Mutations in the glucocerebrosidase gene and Parkinson disease: phenotype-genotype correlation Neurology 65 2005 1460 1461
5. P.M. Antony, N.J. Diederich, and R. Balling Parkinson's disease mouse models in translational research Mamm. Genome 22 2011 401 419
6. K. Aquilano, S. Baldelli, G. Rotilio, and M.R. Ciriolo Role of nitric oxide synthases in Parkinson's disease: a review on the antioxidant and anti-inflammatory activity of polyphenols Neurochem. Res. 33 2008 2416 2426
7. S. Arreguin, P. Nelson, S. Padway, M. Shirazi, and C. Pierpont Dopamine complexes of iron in the etiology and pathogenesis of Parkinson's disease J. Inorg. Biochem. 103 2009 87 93
8. P.K. Auluck, H.Y.E. Chan, J.Q. Trojanowski, V.M.Y. Lee, and N.M. Bonini Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease Science (New York, N.Y.) 295 2002 865 868
9. Y. Avramovich-Tirosh, T. Amit, O. Bar-Am, H. Zheng, M. Fridkin, and M.B.H. Youdim Therapeutic targets and potential of the novel brain-permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease J. Neurochem. 100 2007 490 502
10. G. Barja Mitochondrial oxygen radical generation and leak: sites of production in states 4 and 3, organ specificity, and relation to aging and longevity J. Bioenerg. Biomembr. 31 1999 347 366
11. K.J. Barnham, and A.I. Bush Metals in Alzheimer's and Parkinson's diseases Curr. Opin. Chem. Biol. 12 2008 222 228
12. G. Becker, J. Seufert, U. Bogdahn, H. Reichmann, and K. Reiners Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography Neurology 45 1995 182 184
13. D. Ben-Shachar, P. Riederer, and M.B. Youdim Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease J. Neurochem. 57 1991 1609 1614
14. D. Berg, C. Siefker, and G. Becker Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings J. Neurol. 248 2001 684 689
15. D. Berg, W. Roggendorf, U. Schröder, R. Klein, T. Tatschner, and P. Benz Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury Arch. Neurol. 59 2002 999 1005
16. J. Besnard, G.F. Ruda, V. Setola, K. Abecassis, R.M. Rodriguiz, X.P. Huang, S. Norval, M.F. Sassano, A.I. Shin, L.A. Webster, F.R. Simeons, L. Stojanovski, A. Prat, N.G. Seidah, D.B. Constam, G.R. Bickerton, K.D. Read, W.C. Wetsel, I.H. Gilbert, B.L. Roth, and A.L. Hopkins Automated design of ligands to polypharmacological profiles Nature 492 2012 215 220
17. H. Birbes, S. El Bawab, L.M. Obeid, and Y.A. Hannun Mitochondria and ceramide: intertwined roles in regulation of apoptosis Adv. Enzyme Regul. 42 2002 113 129
18. S. Biskup, D.J. Moore, F. Celsi, S. Higashi, A.B. West, and S.A. Andrabi Localization of LRRK2 to membranous and vesicular structures in mammalian brain Ann. Neurol. 60 2006 557 569
19. D. Blum, S. Torch, N. Lambeng, M. Nissou, A.L. Benabid, and R. Sadoul Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease Prog. Neurobiol. 65 2001 135 172
20. K. Boelmans, B. Holst, M. Hackius, J. Finsterbusch, C. Gerloff, and J. Fiehler Brain iron deposition fingerprints in Parkinson's disease and progressive supranuclear palsy Mov. Disord. 27 2012 421 427
21. S. Bolognin, D. Drago, L. Messori, and P. Zatta Chelation therapy for neurodegenerative diseases Med. Res. Rev. 29 2009 547 570
22. S. Bolognin, L. Messori, and P. Zatta Metal ion physiopathology in neurodegenerative disorders NeuroMol. Med. 11 2009 223 238
23. V. Bonifati, P. Rizzu, M.J. van Baren, O. Schaap, G.J. Breedveld, and E. Krieger Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism Science (New York, N.Y.) 299 2003 256 259
24. S. Bornholdt, and K. Sneppen Robustness as an evolutionary principle Proc. Biol. Sci. 267 2000 2281 2286
25. J. Bové, D. Prou, C. Perier, and S. Przedborski Toxin-induced models of Parkinson's disease NeuroRx 2 2005 484 494
26. N. Bowern, I.A. Ramshaw, I.A. Clark, and P.C. Doherty Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent J. Exp. Med. 160 1984 1532 1543
27. H. Braak, K. Del Tredici, U. Rüb, R.A.I. de Vos, E.N.H. Jansen Steur, and E. Braak Staging of brain pathology related to sporadic Parkinson's disease Neurobiol. Aging 24 2003 197 211
28. J. Bras, A. Verloes, S.A. Schneider, S.E. Mole, and R.J. Guerreiro Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis Hum. Mol. Genet. 21 2012 2646 2650
29. J.M. Bras, and A. Singleton Genetic susceptibility in Parkinson's disease Biochim. Biophys. Acta 1792 2009 597 603
30. D.R. Brown Metal binding to alpha-synuclein peptides and its contribution to toxicity Biochem. Biophys. Res. Commun. 380 2009 377 381
31. N. Brüggemann, J. Hagenah, K. Reetz, A. Schmidt, M. Kasten, and I. Buchmann Recessively inherited parkinsonism: effect of ATP13A2 mutations on the clinical and neuroimaging phenotype Arch. Neurol. 67 2010 1357 1363
32. R.E. Burke Programmed cell death in Parkinson's disease Handb. Clin. Neurol. 83 2007 591 605
33. E. Butelli, L. Titta, M. Giorgio, H.-P. Mock, A. Matros, and S. Peterek Enrichment of tomato fruit with health-promoting anthocyanins by expression of select transcription factors Nat. Biotechnol. 26 2008 1301 1308
34. R.M. Canet-Avilés, M.A. Wilson, D.W. Miller, R. Ahmad, C. McLendon, and S. Bandyopadhyay The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization Proc. Natl. Acad. Sci. USA 101 2004 9103 9108
35. J. Chao, W.K. Lau, M.J. Huie, Y.S. Ho, M.S. Yu, and C.S. Lai A pro-drug of the green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG) prevents differentiated SH-SY5Y cells from toxicity induced by 6-hydroxydopamine Neurosci. Lett. 469 2010 360 364
36. K.R. Chaudhuri, and A.H.V. Schapira Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment Lancet Neurol. 8 2009 464 474
37. Y. Cheng, G. He, X. Mu, T. Zhang, X. Li, and J. Hu Neuroprotective effect of baicalein against MPTP neurotoxicity: behavioral, biochemical and immunohistochemical profile Neurosci. Lett. 441 2008 16 20
38. K.C. Chew, E.T. Ang, Y.K. Tai, F. Tsang, S.Q. Lo, and E. Ong Enhanced autophagy from chronic toxicity of iron and mutant A53T alpha-synuclein: implications for neuronal cell death in Parkinson disease J. Biol. Chem. 286 2011 33380 33389
39. J. Chifman, A. Kniss, P. Neupane, I. Williams, B. Leung, Z. Deng, P. Mendes, V. Hower, F.M. Torti, S.A. Akman, S.V. Torti, and R. Laubenbacher The core control system of intracellular iron homeostasis: a mathematical model J. Theor. Biol. 300 2012 91 99
40. K.K. Chung, B. Thomas, X. Li, O. Pletnikova, J.C. Troncoso, and L. Marsh S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function Science 304 2004 1328 1331
41. S.J. Chung, S.M. Armasu, J.M. Biernacka, T.G. Lesnick, D.N. Rider, and S.J. Lincoln Common variants in PARK loci and related genes and Parkinson's disease Mov. Disord. 26 2011 280 288
42. I.E. Clark, M.W. Dodson, C. Jiang, J.H. Cao, J.R. Huh, and J.H. Seol Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin Nature 441 2006 1162 1166
43. L.N. Clark, A. Nicolai, S. Afridi, J. Harris, H. Mejia-Santana, and L. Strug Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity Mov. Disord. 20 2005 100 103
44. L.N. Clark, B.M. Ross, Y. Wang, H. Mejia-Santana, J. Harris, and E.D. Louis Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease Neurology 69 2007 1270 1277
45. M. Colombini Ceramide channels and their role in mitochondria-mediated apoptosis Biochim. Biophys. Acta 1797 2010 1239 1244
46. D.R. Crapper McLachlan, A.J. Dalton, T.P. Kruck, M.Y. Bell, W.L. Smith, and W. Kalow Intramuscular desferrioxamine in patients with Alzheimer's disease Lancet 337 1991 1304 1308
47. R.R. Crichton, D.T. Dexter, and R.J. Ward Brain iron metabolism and its perturbation in neurological diseases J. Neural Transm. 118 2011 301 314
48. V. Cullen, S.P. Sardi, J. Ng, Y.-H. Xu, Y. Sun, and J.J. Tomlinson Acid β-glucosidase mutants linked to gaucher disease, parkinson disease, and lewy body dementia alter α-synuclein processing Ann. Neurol. 2011
49. S.R. Danielson, J.M. Held, M. Oo, R. Riley, B.W. Gibson, and J.K. Andersen Quantitative mapping of reversible mitochondrial Complex I cysteine oxidation in a Parkinson disease mouse model J. Biol. Chem. 286 2011 7601 7608
50. D. Das, X. Luo, A. Singh, Y. Gu, S. Ghosh, and C.K. Mukhopadhyay Paradoxical role of prion protein aggregates in redox-iron induced toxicity PLoS ONE 5 2010 e11420
51. H.M. Davey, and D.B. Kell Flow cytometry and cell sorting of heterogeneous microbial populations: the importance of single-cell analysis Microbiol. Rev. 60 1996 641 696
52. P. Davies, D. Moualla, and D.R. Brown Alpha-synuclein is a cellular ferrireductase PLoS ONE 6 2011 e15814 e15815
53. T.M. Dawson, and V.L. Dawson Molecular pathways of neurodegeneration in Parkinson's disease Science 302 2003 819 822
54. M. Degli Esposti, and H. McLennan Mitochondria and cells produce reactive oxygen species in virtual anaerobiosis: relevance to ceramide-induced apoptosis FEBS Lett. 430 1998 338 342
55. B. Dehay, J. Bove, N. Rodriguez-Muela, C. Perier, A. Recasens, and P. Boya Pathogenic lysosomal depletion in Parkinson's disease J. Neurosci. 30 2010 12535 12544
56. L. Devi, V. Raghavendran, B.M. Prabhu, N.G. Avadhani, and H.K. Anandatheerthavarada Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain J. Biol. Chem. 283 2008 9089 9100
57. D.T. Dexter, F.R. Wells, A.J. Lees, F. Agid, Y. Agid, and P. Jenner Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease J. Neurochem. 52 1989 1830 1836
58. D.T. Dexter, S.A. Statton, C. Whitmore, W. Freinbichler, P. Weinberger, and K.F. Tipton Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration J Neural Transm. 118 2011 223 231
59. A. Di Fonzo, C.F. Rohé, J. Ferreira, H.F. Chien, L. Vacca, and F. Stocchi A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease Lancet 365 2005 412 415
60. A. Di Fonzo, M.C.J. Dekker, P. Montagna, A. Baruzzi, E.H. Yonova, and L. Correia Guedes FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome Neurology 72 2009 240 245
61. G. Di Giovanni A diet for dopaminergic neurons? J. Neural Transm. Suppl. 2009 317 331
62. V. di Matteo, M. Pierucci, G. Di Giovanni, L.K. Dragani, S. Murzilli, and A. Poggi Intake of tomato-enriched diet protects from 6-hydroxydopamine-induced degeneration of rat nigral dopaminergic neurons J. Neural Transm. Suppl. 2009 333 341
63. M. Di Paola, T. Cocco, and M. Lorusso Ceramide interaction with the respiratory chain of heart mitochondria Biochemistry 39 2000 6660 6668
64. C.B. Do, J.Y. Tung, E. Dorfman, A.K. Kiefer, E.M. Drabant, and U. Francke Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease PLoS Genet. 7 2011 e1002141 e1002142
65. P.D. Dobson, and D.B. Kell Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat. Rev. Drug Disc. 7 2008 205 220
66. K.L. Double, V.N. Dedov, H. Fedorow, E. Kettle, G.M. Halliday, and B. Garner The comparative biology of neuromelanin and lipofuscin in the human brain Cell. Mol. Life Sci. 65 2008 1669 1682
67. D.A. Drechsel, and M. Patel Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease Free Radic. Biol. Med. 44 2008 1873 1886
68. W. Dröge Free radicals in the physiological control of cell function Physiol. Rev. 82 2002 47 95
69. X.X. Du, H.M. Xu, H. Jiang, N. Song, J. Wang, and J.X. Xie Curcumin protects nigral dopaminergic neurons by iron-chelation in the 6-hydroxydopamine rat model of Parkinson's disease Neurosci. Bull. 28 2012 253 258
70. J.E. Duda, B.I. Giasson, M.E. Mabon, D.C. Miller, L.I. Golbe, and V.M.Y. Lee Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred Acta Neuropathol. 104 2002 7 11
71. P. Dusek, J. Jankovic, and W. Le Iron dysregulation in movement disorders Neurobiol Dis. 46 2012 1 18
72. D.J. Dwyer, M.A. Kohanski, and J.J. Collins Role of reactive oxygen species in antibiotic action and resistance Curr. Opin. Microbiol. 12 2009 482 489
73. M. Ebadi, S. Sharma, D. Muralikrishnan, S. Shavali, J. Eken, and P. Sangchot Metallothionein provides ubiquinone-mediated neuroprotection in Parkinson's disease Proc. West. Pharmacol. Soc. 45 2002 36 38
74. M. Ebadi, H. Brown-Borg, H. El Refaey, B.B. Singh, S. Garrett, and S. Shavali Metallothionein-mediated neuroprotection in genetically engineered mouse models of Parkinson's disease Brain Res. Mol. Brain Res. 134 2005 67 75
75. M. Ebadi, S.K. Sharma, P. Ghafourifar, H. Brown-Borg, and H. El Refaey Peroxynitrite in the pathogenesis of Parkinson's disease and the neuroprotective role of metallothioneins Methods Enzymol. 396 2005 276 298
76. M. Ebadi, and S. Sharma Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson disease Exp. Biol. Med. 231 2006 1576 1583
77. M.J. Eblan, J. Nguyen, S.G. Ziegler, A. Lwin, M. Hanson, and M. Gallardo Glucocerebrosidase mutations are also found in subjects with early-onset parkinsonism from Venezuela Mov. Disord. 21 2006 282 283
78. L.A. Engel, Z. Jing, D.E. O'Brien, M. Sun, and P.T. Kotzbauer Catalytic function of PLA2G6 is impaired by mutations associated with infantile neuroaxonal dystrophy but not dystonia-parkinsonism PLoS ONE 5 2010 e12897 e12898
79. S. Fakih, M. Podinovskaia, X. Kong, H.L. Collins, U.E. Schaible, and R.C. Hider Targeting the lysosome: fluorescent iron(III) chelators to selectively monitor endosomal/lysosomal labile iron pools J. Med. Chem. 51 2008 4539 4552
80. S. Fakih, M. Podinovskaia, X. Kong, U.E. Schaible, H.L. Collins, and R.C. Hider Monitoring intracellular labile iron pools: a novel fluorescent iron(III) sensor as a potential non-invasive diagnosis tool J. Pharm. Sci. 98 2009 2212 2226
81. R. Fato, C. Bergamini, S. Leoni, P. Strocchi, and G. Lenaz Generation of reactive oxygen species by mitochondrial complex I: implications in neurodegeneration Neurochem. Res. 33 2008 2487 2501
82. R. Fato, C. Bergamini, S. Leoni, P. Strocchi, and G. Lenaz Generation of reactive oxygen species by mitochondrial complex I: implications in neurodegeneration Neurochem. Res. 33 2008 2487 2501
83. V. France-Lanord, B. Brugg, P.P. Michel, Y. Agid, and M. Ruberg Mitochondrial free radical signal in ceramide-dependent apoptosis: a putative mechanism for neuronal death in Parkinson's disease J. Neurochem. 69 1997 1612 1621
84. V. France-Lanord, B. Brugg, P.P. Michel, Y. Agid, and M. Ruberg Mitochondrial free radical signal in ceramide-dependent apoptosis: a putative mechanism for neuronal death in Parkinson's disease J. Neurochem. 69 1997 1612 1621
85. A.L. Friedlich, R.E. Tanzi, and J.T. Rogers The 5′-untranslated region of Parkinson's disease alpha-synuclein messengerRNA contains a predicted iron responsive element Mol. Psychiatry 12 2007 222 223
86. A. Gaeta, F. Molina-Holgado, X.L. Kong, S. Salvage, S. Fakih, and P.T. Francis Synthesis, physical-chemical characterisation and biological evaluation of novel 2-amido-3-hydroxypyridin-4(1H)-ones: iron chelators with the potential for treating Alzheimer's disease Bioorg. Med. Chem. 19 2011 1285 1297
87. S. Gal, H. Zheng, M. Fridkin, and M.B. Youdim Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30 2009 Neurotox. Res.
88. J. Galazka-Friedman, E.R. Bauminger, K. Szlachta, and A. Friedman The role of iron in neurodegeneration-Mossbauer spectroscopy, electron microscopy, enzyme-linked immunosorbent assay and neuroimaging studies J. Phys. 24 2012 244106
89. J.E. Galvin, V.M. Lee, M. Baba, D.M. Mann, D.W. Dickson, and H. Yamaguchi Monoclonal antibodies to purified cortical Lewy bodies recognize the mid-size neurofilament subunit Ann. Neurol. 42 1997 595 603
90. P.N. Gandhi, S.G. Chen, and A.L. Wilson-Delfosse Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease J. Neurosci. Res. 87 2009 1283 1295
91. M.D. Garrick, L. Zhao, J.A. Roth, H. Jiang, J. Feng, and N.J. Foot Isoform specific regulation of divalent metal (ion) transporter (DMT1) by proteasomal degradation Biometals 2012
92. M.E. Gegg, J.M. Cooper, A.H.V. Schapira, and J.-W. Taanman Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in dopaminergic cells PLoS ONE 4 2009 e4756 e4757
93. M. Gerlach, D. Ben-Shachar, P. Riederer, and M.B. Youdim Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63 1994 793 807
94. B.F. Gh Popescu, and H. Nichol Mapping brain metals to evaluate therapies for neurodegenerative disease CNS Neurosci. Ther. 2010
95. M. Ghosh, F. Carlsson, A. Laskar, X.-M. Yuan, and W. Li Lysosomal membrane permeabilization causes oxidative stress and ferritin induction in macrophages FEBS Lett. 585 2011 623 629
96. W.R. Gibb Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson's disease Brain Res. Mol. Brain Res. 581 1992 283 291
97. W.P. Gilks, P.M. Abou-Sleiman, S. Gandhi, S. Jain, A. Singleton, and A.J. Lees A common LRRK2 mutation in idiopathic Parkinson's disease Lancet 365 2005 415 416
98. M. Goedert Alpha-synuclein and neurodegenerative diseases Nat. Rev. Neurosci. 2 2001 492 501
99. S. Gogoi, T. Antonio, S. Rajagopalan, M. Reith, J. Andersen, and A.K. Dutta Dopamine D(2)/D(3) agonists with potent iron chelation, antioxidant and neuroprotective properties: potential implication in symptomatic and neuroprotective treatment of Parkinson's disease ChemMedChem 6 2011 991 995
100. O. Goker-Alpan, R. Schiffmann, M.E. LaMarca, R.L. Nussbaum, A. McInerney-Leo, and E. Sidransky Parkinsonism among Gaucher disease carriers J. Med. Genet. 41 2004 937 940
101. M. Gorria, X. Tekpli, M. Rissel, O. Sergent, L. Huc, and N. Landvik A new lactoferrin- and iron-dependent lysosomal death pathway is induced by benzo[a]pyrene in hepatic epithelial cells Toxicol. Appl. Pharmacol. 228 2008 212 224
102. M.E. Götz, K. Double, M. Gerlach, M.B.H. Youdim, and P. Riederer The relevance of iron in the pathogenesis of Parkinson's disease Ann. N. Y. Acad. Sci. 1012 2004 193 208
103. G.A. Grabowski Phenotype, diagnosis, and treatment of Gaucher's disease Lancet 372 2008 1263 1271
104. E. Greggio, S. Jain, A. Kingsbury, R. Bandopadhyay, P. Lewis, and A. Kaganovich Kinase activity is required for the toxic effects of mutant LRRK2/dardarin Neurobiol. Dis. 23 2006 329 341
105. A. Gregory, B.J. Polster, and S.J. Hayflick Clinical and genetic delineation of neurodegeneration with brain iron accumulation J. Med. Genet. 46 2009 73 80
106. Z. Gu, T. Nakamura, and S.A. Lipton Redox reactions induced by nitrosative stress mediate protein misfolding and mitochondrial dysfunction in neurodegenerative diseases Mol. Neurobiol. 41 2010 55 72
107. S. Guo, J. Yan, T. Yang, X. Yang, E. Bezard, and B. Zhao Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson's disease through inhibition of ROS-NO pathway Biol. Psychiatry 62 2007 1353 1362
108. B. Hallgren, and P. Sourander The effect of age on the non-haemin iron in the human brain J. Neurochem. 3 1958 41 51
109. B. Halliwell, and M.C. Gutteridge Free Radicals in Biology and Medicine 2006 Oxford University Press
110. J. Hardy, P. Lewis, T. Revesz, A. Lees, and C. Paisan-Ruiz The genetics of Parkinson's syndromes: a critical review Curr. Opin. Genet. Dev. 19 2009 254 265
111. J. Hardy Genetic analysis of pathways to Parkinson disease Neuron 68 2010 201 206
112. A. Hartley, J.M. Stone, C. Heron, J.M. Cooper, and A.H. Schapira Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease J. Neurochem. 63 1994 1987 1990
113. T. Hatano, S.-I. Kubo, S. Imai, M. Maeda, K. Ishikawa, and Y. Mizuno Leucine-rich repeat kinase 2 associates with lipid rafts Hum. Mol. Genet. 16 2007 678 690
114. S.J. Hayflick Unraveling the Hallervorden-Spatz syndrome: pantothenate kinase-associated neurodegeneration is the name Curr. Opin. Pediatr. 15 2003 572 577
115. S.J. Hayflick Neurodegeneration with brain iron accumulation: from genes to pathogenesis Semin. Pediatr. Neurol. 13 2006 182 185
116. Q. He, N. Song, H. Xu, R. Wang, J. Xie, and H. Jiang Alpha-synuclein aggregation is involved in the toxicity induced by ferric iron to SK-N-SH neuroblastoma cells J. Neural Transm. 2010
117. Q. He, T. Du, X. Yu, A. Xie, N. Song, and Q. Kang DMT1 polymorphism and risk of Parkinson's disease Neurosci. Lett. 501 2011 128 131
118. D.G. Healy, M. Falchi, S.S. O'Sullivan, V. Bonifati, A. Durr, and S. Bressman Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study Lancet Neurol. 7 2008 583 590
119. B.D. Heavner, K. Smallbone, B. Barker, P. Mendes, and L.P. Walker Yeast 5-an expanded reconstruction of the Saccharomyces Cerevisiae metabolic network BMC Syst. Biol. 6 2012 55
120. C. Henchcliffe, and M.F. Beal Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis Nat. Clin. Pract. Neurol. 4 2008 600 609
121. M.J. Herrgård, N. Swainston, P. Dobson, W.B. Dunn, K.Y. Arga, and M. Arvas A consensus yeast metabolic network reconstruction obtained from a community approach to systems biology Nat. Biotechnol. 26 2008 1155 1160
122. R.C. Hider, S. Roy, Y.M. Ma, X. Le Kong, and J. Preston The potential application of iron chelators for the treatment of neurodegenerative diseases Metallomics 3 2011 239 249
123. A.S. Hillmer, P. Putcha, J. Levin, T. Högen, B.T. Hyman, and H. Kretzschmar Converse modulation of toxic alpha-synuclein oligomers in living cells by N′-benzylidene-benzohydrazide derivates and ferric iron Biochem. Biophys. Res. Commun. 391 2010 461 466
124. L. Hood Systems biology: integrating technology, biology, and computation Mech. Ageing Dev. 124 2003 9 16
125. A.L. Hopkins, J.S. Mason, and J.P. Overington Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 16 2006 127 136
126. A.L. Hopkins Network pharmacology: the next paradigm in drug discovery Nat. Chem. Biol. 4 2008 682 690
127. H. Houlden, and A.B. Singleton The genetics and neuropathology of Parkinson's disease Acta Neuropathol. 124 2012 325 338
128. V. Hower, P. Mendes, F.M. Torti, R. Laubenbacher, S. Akman, V. Shulaev, and S.V. Torti A general map of iron metabolism and tissue-specific subnetworks Mol. Biosyst. 5 2009 422 443
129. T. Ideker, T. Galitski, and L. Hood A new approach to decoding life: systems biology Annu. Rev. Genomics Hum. Genet. 2 2001 343 372
130. K. Ii, H. Ito, K. Tanaka, and A. Hirano Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly J. Neuropathol. Exp. Neurol. 56 1997 125 131
131. M. Jaleel, R.J. Nichols, M. Deak, D.G. Campbell, F. Gillardon, and A. Knebel LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity Biochem. J. 405 2007 307 317
132. A. Jana, E.L. Hogan, and K. Pahan Ceramide and neurodegeneration: susceptibility of neurons and oligodendrocytes to cell damage and death J. Neurol. Sci. 278 2009 5 15
133. K.A. Jellinger Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts Mov. Disord. 27 2012 8 30
134. P. Jenner, and C.W. Olanow The pathogenesis of cell death in Parkinson's disease Neurology 66 2006 S24 S36
135. J. Jin, T. Cardozo, R.C. Lovering, S.J. Elledge, M. Pagano, and J.W. Harper Systematic analysis and nomenclature of mammalian F-box proteins Genes Dev. 18 2004 2573 2580
136. K. Jomova, D. Vondrakova, M. Lawson, and M. Valko Metals, oxidative stress and neurodegenerative disorders Mol. Cell. Biochem. 345 2010 91 104
137. K. Jomova, D. Vondrakova, M. Lawson, and M. Valko Metals, oxidative stress and neurodegenerative disorders Mol. Cell. Biochem. 8 2010 9
138. K. Jomova, and M. Valko Importance of iron chelation in free radical-induced oxidative stress and human disease Curr. Pharm. Des. 17 2011 3460 3473
139. K. Jomova, and M. Valko Advances in metal-induced oxidative stress and human disease Toxicology 283 2011 65 87
140. A. Kastner, E.C. Hirsch, O. Lejeune, F. Javoy-Agid, O. Rascol, and Y. Agid Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J. Neurochem. 59 1992 1080 1089
141. D. Kaur, F. Yantiri, S. Rajagopalan, J. Kumar, J.Q. Mo, and R. Boonplueang Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease Neuron 37 2003 899 909
142. J.P. Kehrer The Haber-Weiss reaction and mechanisms of toxicity Toxicology 149 2000 43 50
143. D.B. Kell The protonmotive force as an intermediate in electron transport-linked phosphorylation: problems and prospects Curr. Top. Cell. Regul. 33 1992 279 289
144. D.B. Kell, and J.D. Knowles The Role Of Modeling In Systems Biology. System Modeling in Cellular Biology: from Concepts To Nuts And Bolts 2006 MIT Press Cambridge pp. 3-18
145. D.B. Kell The virtual human: towards a global systems biology of multiscale, distributed biochemical network models IUBMB Life 59 2007 689 695
146. D.B. Kell, and P. Mendes The markup is the model: reasoning about systems biology models in the Semantic Web era J. Theor. Biol. 252 2008 538 543
147. D.B. Kell Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases BMC Med. Genomics 2 2009 2
148. D.B. Kell Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases BMC Med. Genomics 2 2009 2
149. D.B. Kell Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples Arch. Toxicol. 577 2010 825 889 10.1007/s00204-010-0577-x
150. D.B. Kell Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples Arch. Toxicol. 84 2010 825 889
151. D.B. Kell, P.D. Dobson, and S.G. Oliver Pharmaceutical drug transport: the issues and the implications that it is essentially carrier-mediated only Drug Disc. Today 16 2011 704 714
152. Kell, D.B., Dobson, P.D., Bilsland, E., Oliver, S.G., 2012. The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so. Drug Disc. Today, in press.
153. J.F. Kerr, A.H. Wyllie, and A.R. Currie Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics Br. J. Cancer 26 1972 239 257
154. T. Kitada, S. Asakawa, N. Hattori, H. Matsumine, Y. Yamamura, and S. Minoshima Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism Nature 392 1998 605 608
155. H. Kitano Computational systems biology Nature 420 2002 206 210
156. H. Kitano Biological robustness Nat. Rev. Genet. 5 2004 826 837
157. M.A. Kohanski, D.J. Dwyer, B. Hayete, C.A. Lawrence, and J.J. Collins A common mechanism of cellular death induced by bactericidal antibiotics Cell 130 2007 797 810
158. P. Kooncumchoo, S. Sharma, J. Porter, P. Govitrapong, and M. Ebadi Coenzyme Q(10) provides neuroprotection in iron-induced apoptosis in dopaminergic neurons J. Mol. Neurosci. 28 2006 125 141
159. R.M. Kostrzewa Review of apoptosis vs. necrosis of substantia nigra pars compacta in Parkinson's disease Neurotox. Res. 2 2000 239 250
160. A. Koutsoukas, B. Simms, J. Kirchmair, P.J. Bond, A.V. Whitmore, and S. Zimmer From in silico target prediction to multi-target drug design: current databases, methods and applications J. Proteomics 74 2011 2554 2574
161. G. Krebiehl, S. Ruckerbauer, L.F. Burbulla, N. Kieper, B. Maurer, and J. Waak Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-1 PLoS ONE 5 2010 e9367 e9368
162. M.C. Kruer, C. Paisán-Ruiz, N. Boddaert, M.Y. Yoon, H. Hama, and A. Gregory Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA) Ann. Neurol. 68 2010 611 618
163. M.C. Kruer, M. Hiken, A. Gregory, A. Malandrini, D. Clark, and P. Hogarth Novel histopathologic findings in molecularly-confirmed pantothenate kinase-associated neurodegeneration Brain 134 2011 947 958
164. U. Kumari, and E.K. Tan LRRK2 in Parkinson's disease: genetic and clinical studies from patients FEBS J. 276 2009 6455 6463
165. L. Kupershmidt, T. Amit, O. Bar-Am, M.B. Youdim, and O. Weinreb Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice Mech. Ageing Dev. 133 2012 267 274
166. T. Kurz, A. Leake, T. von Zglinicki, and U.T. Brunk Relocalized redox-active lysosomal iron is an important mediator of oxidative-stress-induced DNA damage Biochem. J. 378 2004 1039 1045
167. T. Kurz, A. Terman, and U.T. Brunk Autophagy, ageing and apoptosis: the role of oxidative stress and lysosomal iron Arch. Biochem. Biophys. 462 2007 220 230
168. T. Kurz, A. Terman, B. Gustafsson, and U.T. Brunk Lysosomes and oxidative stress in aging and apoptosis Biochim. Biophys. Acta 1780 2008 1291 1303
169. T. Kurz, A. Terman, B. Gustafsson, and U.T. Brunk Lysosomes in iron metabolism, ageing and apoptosis Histochem. Cell Biol. 129 2008 389 406
170. S. Kuzuhara, H. Mori, N. Izumiyama, M. Yoshimura, and Y. Ihara Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study Acta Neuropathol. 75 1988 345 353
171. J. Lan, and D.H. Jiang Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice J. Neural Transm. 104 1997 469 481
172. A.E. Lang The progression of Parkinson disease: a hypothesis Neurology 68 2007 948 952
173. M.J. LaVoie, B.L. Ostaszewski, A. Weihofen, M.G. Schlossmacher, and D.J. Selkoe Dopamine covalently modifies and functionally inactivates parkin Nat. Med. 11 2005 1214 1221
174. M.J. LaVoie, G.P. Cortese, B.L. Ostaszewski, and M.G. Schlossmacher The effects of oxidative stress on parkin and other E3 ligases J. Neurochem. 103 2007 2354 2368
175. N. Le Novère, M. Hucka, H. Mi, S. Moodie, F. Schreiber, and A. Sorokin The systems biology graphical notation Nat. Biotechnol. 27 2009 735 741
176. J. Lehar, A.S. Krueger, W. Avery, A.M. Heilbut, L.M. Johansen, and E.R. Price Synergistic drug combinations tend to improve therapeutically relevant selectivity Nat. Biotechnol. 27 2009 659 666
177. J. Lehár, G.R. Zimmermann, A.S. Krueger, R.A. Molnar, J.T. Ledell, and A.M. Heilbut Chemical combination effects predict connectivity in biological systems Mol. Sys. Biol. 3 2007 80-80
178. J. Lehár, B.R. Stockwell, G. Giaever, and C. Nislow Combination chemical genetics Nat. Chem. Biol. 4 2008 674 681
179. P. Lei, S. Ayton, D.I. Finkelstein, L. Spoerri, G.D. Ciccotosto, and D.K. Wright Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export Nat. Med. 18 2012 291 295
180. S. Lesage, and A. Brice Parkinson's disease: from monogenic forms to genetic susceptibility factors Hum. Mol. Genet. 18 2009 R48 R59
181. N. Lev, E. Melamed, and D. Offen Apoptosis and Parkinson's disease Prog. Neuropsychopharmacol. Biol. Psychiatry 27 2003 245 250
182. N. Lev, D. Ickowicz, E. Melamed, and D. Offen Oxidative insults induce DJ-1 upregulation and redistribution: implications for neuroprotection Neurotoxicology 29 2008 397 405
183. C.W. Levenson Iron and Parkinson's disease: chelators to the rescue? Nutr. Rev. 61 2003 311 313
184. C.W. Levenson, R.G. Cutler, B. Ladenheim, J.L. Cadet, J. Hare, and M.P. Mattson Role of dietary iron restriction in a mouse model of Parkinson's disease Exp. Neurol. 190 2004 506 514
185. C.W. Levenson, R.G. Cutler, B. Ladenheim, J.L. Cadet, J. Hare, and M.P. Mattson Role of dietary iron restriction in a mouse model of Parkinson's disease Exp. Neurol. 190 2004 506 514
186. Y. Levites, O. Weinreb, G. Maor, M.B. Youdim, and S. Mandel Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced dopaminergic neurodegeneration J. Neurochem. 78 2001 1073 1082
187. H.M. Li, T. Niki, T. Taira, S.M.M. Iguchi-Ariga, and H. Ariga Association of DJ-1 with chaperones and enhanced association and colocalization with mitochondrial Hsp70 by oxidative stress Free Radical Res. 39 2005 1091 1099
188. W.-J. Li, H. Jiang, N. Song, and J.-X. Xie Dose- and time-dependent alpha-synuclein aggregation induced by ferric iron in SK-N-SH cells Neurosci. Bull. 26 2010 205 210
189. W. Li, H. Jiang, N. Song, and J. Xie Oxidative stress partially contributes to iron-induced alpha-synuclein aggregation in SK-N-SH cells 2010 Neurotox. Res.
190. V. Licker, E. Kövari, D.F. Hochstrasser, and P.R. Burkhard Proteomics in human Parkinson's disease research J. Proteomics 73 2009 10 29
191. K.L. Lim, V.L. Dawson, and T.M. Dawson The genetics of Parkinson's disease Curr. Neurol. Neurosci. Rep. 2 2002 439 446
192. S.A. Lipton, T. Nakamura, D. Yao, Z.-Q. Shi, T. Uehara, and Z. Gu Comment on "S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function" Science (New York, N.Y.) 308 2005 1870 author reply 1870-1870; author reply 1870
193. Z. Liu, S. Hamamichi, B.D. Lee, D. Yang, A. Ray, and G.A. Caldwell Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and drosophila Parkinson's disease models Hum. Mol. Genet. 20 2011 3933 3942
194. J. Lotharius, and P. Brundin Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein Nat. Rev. Neurosci. 3 2002 932 942
195. Z. Lv, H. Jiang, H. Xu, N. Song, and J. Xie Increased iron levels correlate with the selective nigral dopaminergic neuron degeneration in Parkinson's disease J. Neural Transm. 118 2011 361 369
196. A. Lwin, E. Orvisky, O. Goker-Alpan, M.E. LaMarca, and E. Sidransky Glucocerebrosidase mutations in subjects with parkinsonism Mol. Genet. Metab. 81 2004 70 73
197. 2+-independent phospholipase A2 Prog. Nucleic Acid Res. Mol. Biol. 67 2001 1 33
198. W. Maetzler, D. Berg, N. Schalamberidze, A. Melms, K. Schott, and J.C. Mueller Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model Neurobiol. Dis. 25 2007 473 482
199. W. Maetzler, I. Liepelt, and D. Berg Progression of Parkinson's disease in the clinical phase: potential markers Lancet Neurol. 8 2009 1158 1171
200. J.C. Mak Potential role of green tea catechins in various disease therapies: progress and promise Clin. Exp. Pharmacol. Physiol. 39 2012 265 273
201. I. Malik, J. Turk, D.J. Mancuso, L. Montier, M. Wohltmann, and D.F. Wozniak Disrupted membrane homeostasis and accumulation of ubiquitinated proteins in a mouse model of infantile neuroaxonal dystrophy caused by PLA2G6 mutations Am. J. Pathol. 172 2008 406 416
202. S.A. Mandel, T. Amit, O. Weinreb, L. Reznichenko, and M.B. Youdim Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases CNS Neurosci. Ther. 14 2008 352 365
203. S.A. Mandel, and M.B. Youdim In the rush for green gold: can green tea delay age-progressive brain neurodegeneration? Recent Pat. CNS Drug Discovery 7 2012 205 217
204. T.A. Manolio, F.S. Collins, N.J. Cox, D.B. Goldstein, L.A. Hindorff, and D.J. Hunter Finding the missing heritability of complex diseases Nature 461 2009 747 753
205. W.R.W. Martin Quantitative estimation of regional brain iron with magnetic resonance imaging Parkinsonism Relat. Disord. 15 Suppl 3 2009 S215 S218
206. W. Maruyama, Y. Akao, M.C. Carrillo, K. Kitani, M.B.H. Youdim, and M. Naoi Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes Neurotoxicol. Teratol. 24 2002 675 682
207. C.C. McCulloch, D.M. Kay, S.A. Factor, A. Samii, J.G. Nutt, and D.S. Higgins Exploring gene-environment interactions in Parkinson's disease Hum. Genet. 123 2008 257 265
208. A. McNeill PLA2G6 mutations and other rare causes of neurodegeneration with brain iron accumulation Curr. Drug Targets 13 2012 1204 1206
209. N.P. Mena, A.L. Bulteau, J. Salazar, E.C. Hirsch, and M.T. Nunez Effect of mitochondrial complex I inhibition on Fe-S cluster protein activity Biochem. Biophys. Res. Commun. 409 2011 241 246
210. L.D. Mercer, B.L. Kelly, M.K. Horne, and P.M. Beart Dietary polyphenols protect dopamine neurons from oxidative insults and apoptosis: investigations in primary rat mesencephalic cultures Biochem. Pharmacol. 69 2005 339 345
211. D.W. Miller, R. Ahmad, S. Hague, M.J. Baptista, R. Canet-Aviles, and C. McLendon L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system J. Biol. Chem. 278 2003 36588 36595
212. R.L. Miller, M. James-Kracke, G.Y. Sun, and A.Y. Sun Oxidative and inflammatory pathways in Parkinson's disease Neurochem. Res. 34 2009 55 65
213. H. Mochizuki, and T. Yasuda Iron accumulation in Parkinson's disease J. Neural Transm. Suppl. 2012
214. D.J. Moore Parkin: a multifaceted ubiquitin ligase Biochem. Soc. Trans. 34 2006 749 753
215. H. Mortiboys, K.K. Johansen, J.O. Aasly, and O. Bandmann Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2 Neurology 75 2010 2017 2020
216. R.B. Mounsey, and P. Teismann Chelators in the treatment of iron accumulation in Parkinson's disease Int. J. Cell Biol. 2012 2012 983245
217. X. Mu, G.R. He, X. Yuan, X.X. Li, and G.H. Du Baicalein protects the brain against neuron impairments induced by MPTP in C57BL/6 mice Pharmacol. Biochem. Behav. 98 2011 286 291
218. M.A. Nalls, V. Plagnol, D.G. Hernandez, M. Sharma, U.-M. Sheerin, and M. Saad Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies Lancet 377 2011 641 649
219. A. Napolitano, P. Manini, and M. d'Ischia Oxidation chemistry of catecholamines and neuronal degeneration: an update Curr. Med. Chem. 18 2011 1832 1845
220. W.C. Nichols, N. Pankratz, D. Hernandez, C. Paisán-Ruíz, S. Jain, and C.A. Halter Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease Lancet 365 2005 410 412
221. W.C. Nichols, N. Pankratz, D.K. Marek, M.W. Pauciulo, V.E. Elsaesser, C.A. Halter, A. Rudolph, J. Wojcieszek, R.F. Pfeiffer, and T. Foroud Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset Neurology 72 2009 310 316
222. L. Novikova, B.L. Garris, D.R. Garris, and Y.S. Lau Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease Neuroscience 140 2006 67 76
223. M.T. Nunez, P. Urrutia, N. Mena, P. Aguirre, V. Tapia, and J. Salazar Iron toxicity in neurodegeneration Biometals 25 2012 761 776
224. K. Nuytemans, J. Theuns, M. Cruts, and C. Van Broeckhoven Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update Hum. Mutat. 31 2010 763 780
225. S. Orrenius, V. Gogvadze, and B. Zhivotovsky Mitochondrial oxidative stress: implications for cell death Annu. Rev. Pharmacol. Toxicol. 47 2007 143 183
226. H.F. Ortega-Arellano, M. Jimenez-Del-Rio, and C. Velez-Pardo Life span and locomotor activity modification by glucose and polyphenols in drosophila melanogaster chronically exposed to oxidative stress-stimuli: implications in Parkinson's Disease Neurochem. Res. 2011
227. S. Oshiro, M.S. Morioka, and M. Kikuchi Dysregulation of iron metabolism in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis Adv. Pharmacol. Sci. 2011 2011 378278
228. C. Paisan-Ruiz, K.P. Bhatia, A. Li, D. Hernandez, M. Davis, and N.W. Wood Characterization of PLA2G6 as a locus for dystonia-parkinsonism Ann. Neurol. 65 2009 19 23
229. C. Paisán-Ruiz, R. Guevara, M. Federoff, H. Hanagasi, F. Sina, and E. Elahi Early-onset l-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations Mov. Disord. 25 2010 1791 1800
230. C. Paisán-Ruiz, A. Li, S.A. Schneider, J.L. Holton, R. Johnson, and D. Kidd Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations Neurobiol. Aging 2010
231. C. Paisán-Ruíz, S. Jain, E.W. Evans, W.P. Gilks, J. Simón, and M. van der Brug Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease Neuron 44 2004 595 600
232. A.K. Pandey, R. Patnaik, D.F. Muresanu, A. Sharma, and H.S. Sharma Quercetin in hypoxia-induced oxidative stress: novel target for neuroprotection Int. Rev. Neurobiol. 102 2012 107 146
233. I. Paris, P. Martinez-Alvarado, S. Cárdenas, C. Perez-Pastene, R. Graumann, and P. Fuentes Dopamine-dependent iron toxicity in cells derived from rat hypothalamus Chem. Res. Toxicol. 18 2005 415 419
234. J.-S. Park, P. Mehta, A.A. Cooper, D. Veivers, A. Heimbach, and B. Stiller Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism Hum. Mutat. 32 2011 956 964
235. J. Park, S.B. Lee, S. Lee, Y. Kim, S. Song, and S. Kim Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin Nature 441 2006 1157 1161
236. J.H. Park, K.H. Lee, T.Y. Kim, and S.Y. Lee Metabolic engineering of Escherichia coli for the production of l-valine based on transcriptome analysis and in silico gene knockout simulation Proc. Natl. Acad. Sci. USA 104 2007 7797 7802
237. J. Peng, M.L. Oo, and J.K. Andersen Synergistic effects of environmental risk factors and gene mutations in Parkinson's disease accelerate age-related neurodegeneration J. Neurochem. 2010
238. Y. Peng, C. Wang, H.H. Xu, Y.N. Liu, and F. Zhou Binding of alpha-synuclein with Fe(III) and with Fe(II) and biological implications of the resultant complexes J. Inorg. Biochem. 104 2010 365 370
239. C.A. Perez, Y. Tong, and M. Guo Iron chelators as potential therapeutic agents for Parkinson's disease Curr. Bioact. Compd. 4 2008 150 158
240. C. Perier, J. Bove, D.C. Wu, B. Dehay, D.K. Choi, and V. Jackson-Lewis Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease Proc. Natl. Acad. Sci. USA 104 2007 8161 8166
241. N.R. Perron, and J.L. Brumaghim A review of the antioxidant mechanisms of polyphenol compounds related to iron binding Cell Biochem. Biophys. 53 2009 75 100
242. H.L. Persson Iron-dependent lysosomal destabilization initiates silica-induced apoptosis in murine macrophages Toxicol. Lett. 159 2005 124 133
243. A. Petit, T. Kawarai, E. Paitel, N. Sanjo, M. Maj, and M. Scheid Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations J. Biol. Chem. 280 2005 34025 34032
244. M.K. Phillips, and D.B. Kell A novel inhibitor of NADH dehydrogenase in Paracoccus denitrificans FEBS Lett. 140 1982 248 250
245. A. Pilsl, and K.F. Winklhofer Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinson's disease Acta Neuropathol. 123 2012 173 188
246. H. Plun-Favreau, K. Klupsch, N. Moisoi, S. Gandhi, S. Kjaer, and D. Frith The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1 Nat. Cell Biol. 9 2007 1243 1252
247. M.H. Polymeropoulos, C. Lavedan, E. Leroy, S.E. Ide, A. Dehejia, and A. Dutra Mutation in the alpha-synuclein gene identified in families with Parkinson's disease Science (New York, N.Y.) 276 1997 2045 2047
248. A.C. Poole, R.E. Thomas, L.A. Andrews, H.M. McBride, A.J. Whitworth, and L.J. Pallanck The PINK1/Parkin pathway regulates mitochondrial morphology Proc. Natl. Acad. Sci. USA 105 2008 1638 1643
249. S. Raha, and B.H. Robinson Mitochondria, oxygen free radicals, and apoptosis Am. J. Med. Genet. 106 2001 62 70
250. A. Ramirez, A. Heimbach, J. Gründemann, B. Stiller, D. Hampshire, and L.P. Cid Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase Nat. Genet. 38 2006 1184 1191
251. M. Reale, M. Pesce, M. Priyadarshini, M.A. Kamal, and A. Patruno Mitochondria as an easy target to oxidative stress events in Parkinson's disease CNS Neurol. Disord.: Drug Targets 11 2012 430 438
252. S.L. Rhodes, and B. Ritz Genetics of iron regulation and the possible role of iron in Parkinson's disease Neurobiol. Dis. 32 2008 183 195
253. P. Riederer, E. Sofic, W.D. Rausch, B. Schmidt, G.P. Reynolds, and K. Jellinger Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains J. Neurochem. 52 1989 515 520
254. P. Riederer, A. Dirr, M. Goetz, E. Sofic, K. Jellinger, and M.B. Youdim Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease Ann. Neurol. 32 Suppl 1992 S101 S104
255. P. Riederer, and M.B.H. Youdim Iron in Central Nervous Systems Disorders 1993 Springer Vienna, Austria
256. I. Ron, D. Rapaport, and M. Horowitz Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease Hum. Mol. Genet. 19 2010 3771 3781
257. M. Rossi, H. Ruottinen, I. Elovaara, P. Ryymin, S. Soimakallio, and H. Eskola Brain iron deposition and sequence characteristics in parkinsonism: comparison of SWI, T2 maps, T2-weighted-, and FLAIR-SPACE Invest. Radiol. 2010
258. J.A. Roth, S. Singleton, J. Feng, M. Garrick, and P.N. Paradkar Parkin regulates metal transport via proteasomal degradation of the 1B isoforms of divalent metal transporter 1 J. Neurochem. 113 2010 454 464
259. S.K. Sahoo, D. Sharma, R.K. Bera, G. Crisponi, and J.F. Callan Iron(III) selective molecular and supramolecular fluorescent probes Chem. Soc. Rev. 41 2012 7195 7227
260. N. Saini, S. Oelhafen, H. Hua, O. Georgiev, W. Schaffner, and H. Büeler Extended lifespan of Drosophila parkin mutants through sequestration of redox-active metals and enhancement of anti-oxidative pathways Neurobiol. Dis. 40 2010 82 92
261. J. Salazar, N. Mena, S. Hunot, A. Prigent, D. Alvarez-Fischer, and M. Arredondo Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease Proc. Nat. Acad. Sci. USA 105 2008 18578 18583
262. J. Salazar, N. Mena, S. Hunot, A. Prigent, D. Alvarez-Fischer, and M. Arredondo Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease Proc. Natl. Acad. Sci. USA 105 2008 18578 18583
263. L. Samaranch, O. Lorenzo-Betancor, J.M. Arbelo, I. Ferrer, E. Lorenzo, and J. Irigoyen PINK1-linked parkinsonism is associated with Lewy body pathology Brain 133 2010 1128 1142
264. C. Sato, A. Morgan, A.E. Lang, S. Salehi-Rad, T. Kawarai, and Y. Meng Analysis of the glucocerebrosidase gene in Parkinson's disease Mov. Disord. 20 2005 367 370
265. A.H. Schapira, J.M. Cooper, D. Dexter, P. Jenner, J.B. Clark, and C.D. Marsden Mitochondrial complex I deficiency in Parkinson's disease Lancet 1 1989 1269
266. A.H.V. Schapira Mitochondrial dysfunction in Parkinson's disease Cell Death Differ. 14 2007 1261 1266
267. T.D. Schiano, M. Grinberg, I. Nawabi, and G. Grabowski Blue nasal secretions: a presentation of Gaucher's disease and concurrent hemosiderosis Am. J. Hematol. 44 1993 219 220
268. J.S. Schlehe, A.K. Lutz, A. Pilsl, K. Lammermann, K. Grgur, and I.H. Henn Aberrant folding of pathogenic Parkin mutants: aggregation versus degradation J. Biol. Chem. 283 2008 13771 13779
269. S.A. Schneider, and K.P. Bhatia Rare causes of dystonia parkinsonism Curr. Neurol. Neurosci. Rep. 10 2010 431 439
270. S.A. Schneider, and K.P. Bhatia Three faces of the same gene: FA2H links neurodegeneration with brain iron accumulation, leukodystrophies, and hereditary spastic paraplegias Ann. Neurol. 68 2010 575 577
271. S.A. Schneider, C. Paisan-Ruiz, N.P. Quinn, A.J. Lees, H. Houlden, and J. Hardy ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation Mov. Disord. 25 2010 979 984
272. S.A. Schneider, and K.P. Bhatia Syndromes of neurodegeneration with brain iron accumulation Semin. Pediatr. Neurol. 19 2012 57 66
273. S.A. Schneider, J. Hardy, and K.P. Bhatia Syndromes of neurodegeneration with brain iron accumulation (NBIA): an update on clinical presentations, histological and genetic underpinnings, and treatment considerations Mov. Disord. 27 2012 42 53
274. K.J. Schweitzer, T. Brussel, P. Leitner, R. Kruger, P. Bauer, and D. Woitalla Transcranial ultrasound in different monogenetic subtypes of Parkinson's disease J. Neurol. 254 2007 613 616
275. K.J. Schweitzer, T. Brüssel, P. Leitner, R. Krüger, P. Bauer, and D. Woitalla Transcranial ultrasound in different monogenetic subtypes of Parkinson's disease J. Neurol. 254 2007 613 616
276. D.B. Shachar, N. Kahana, V. Kampel, A. Warshawsky, and M.B.H. Youdim Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats Neuropharmacology 46 2004 254 263
277. J. Shen Protein kinases linked to the pathogenesis of Parkinson's disease Neuron 44 2004 575 577
278. S. Shendelman, A. Jonason, C. Martinat, T. Leete, and A. Abeliovich DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation PLoS Biol. 2 2004 e362 e363
279. T.B. Sherer, R. Betarbet, A.K. Stout, S. Lund, M. Baptista, and A.V. Panov An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage J. Neurosci. 22 2002 7006 7015
280. Z. Shi, G. Nie, X.L. Duan, T. Rouault, W.S. Wu, and B. Ning Neuroprotective mechanism of mitochondrial ferritin on 6-hydroxydopamine induced dopaminergic cell damage: implication for neuroprotection in Parkinson's disease Antioxid. Redox Signal. 13 2010 783 796
281. G. Shinar, and M. Feinberg Structural sources of robustness in biochemical reaction networks Science (New York, N.Y.) 327 2010 1389 1391
282. S. Shojaee, F. Sina, S.S. Banihosseini, M.H. Kazemi, R. Kalhor, and G.-A. Shahidi Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays Am. J. Hum. Genet. 82 2008 1375 1384
283. J. Sian-Hulsmann, S. Mandel, M.B. Youdim, and P. Riederer The relevance of iron in the pathogenesis of Parkinson's disease J. Neurochem. 118 2011 939 957
284. J. Sian-Hülsmann, S. Mandel, M.B.H. Youdim, and P. Riederer The relevance of iron in the pathogenesis of Parkinson's disease J. Neurochem. 2010
285. E. Sidransky, M.A. Nalls, J.O. Aasly, J. Aharon-Peretz, G. Annesi, and E.R. Barbosa Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease N. Engl. J. Med. 361 2009 1651 1661
286. E. Sidransky, T. Samaddar, and N. Tayebi Mutations In GBA are associated with familial Parkinson disease susceptibility and age at onset Neurology 73 2009 1424 1426
287. N. Singh, V. Pillay, and Y.E. Choonara Advances in the treatment of Parkinson's disease Prog. Neurobiol. 81 2007 29 44
288. N. Singh, A. Singh, D. Das, and M.L. Mohan Redox control of prion and disease pathogenesis Antioxid. Redox Signal. 12 2010 1271 1294
289. L.J. Siskind Mitochondrial ceramide and the induction of apoptosis J. Bioenerg. Biomembr. 37 2005 143 153
290. B.G. Small, B.W. McColl, R. Allmendinger, J. Pahle, G. Lopez-Castejon, and N.J. Rothwell Efficient discovery of anti-inflammatory small-molecule combinations using evolutionary computing Nat. Chem. Biol. 7 2011 902 908
291. W.W. Smith, Z. Pei, H. Jiang, D.J. Moore, Y. Liang, and A.B. West Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration Proc. Natl. Acad. Sci. USA 102 2005 18676 18681
292. W.W. Smith, Z. Pei, H. Jiang, V.L. Dawson, T.M. Dawson, and C.A. Ross Kinase activity of mutant LRRK2 mediates neuronal toxicity Nat. Neurosci. 9 2006 1231 1233
293. A.M. Snyder, and J.R. Connor Iron, the substantia nigra and related neurological disorders Biochim. Biophys. Acta 1790 2009 606 614
294. E. Sofic, P. Riederer, H. Heinsen, H. Beckmann, G.P. Reynolds, and G. Hebenstreit Increased iron(III) and total iron content in post mortem substantia nigra of parkinsonian brain J. Neural Transm. Suppl. 74 1988 199 205
295. E. Sofic, W. Paulus, K. Jellinger, P. Riederer, and M.B. Youdim Selective increase of iron in substantia nigra zona compacta of parkinsonian brains J. Neurochem. 56 1991 978 982
296. M.G. Spillantini, M.L. Schmidt, V.M. Lee, J.Q. Trojanowski, R. Jakes, and M. Goedert Alpha-synuclein in Lewy bodies Nature 388 1997 839 840
297. M.G. Spillantini, R.A. Crowther, R. Jakes, M. Hasegawa, and M. Goedert Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies Proc. Natl. Acad. Sci. USA 95 1998 6469 6473
298. J. Stankiewicz, S.S. Panter, M. Neema, A. Arora, C.E. Batt, and R. Bakshi Iron in chronic brain disorders: imaging and neurotherapeutic implications Neurotherapeutics 4 2007 371 386
299. P. Stein, H. Yu, D. Jain, and P.K. Mistry Hyperferritinemia and iron overload in type 1 Gaucher disease Am. J. Hematol. 85 2010 472 476
300. J. Stelling, U. Sauer, Z. Szallasi, F.J. Doyle 3rd, and J. Doyle Robustness of cellular functions Cell 118 2004 675 685
301. F.H. Sterky, A.F. Hoffman, D. Milenkovic, B. Bao, A. Paganelli, and D. Edgar Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons Hum. Mol. Genet. 21 2012 1078 1089
302. K.M. Strauss, L.M. Martins, H. Plun-Favreau, F.P. Marx, S. Kautzmann, and D. Berg Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease Hum. Mol. Genet. 14 2005 2099 2111
303. T. Taira, Y. Saito, T. Niki, S.M.M. Iguchi-Ariga, K. Takahashi, and H. Ariga DJ-1 has a role in antioxidative stress to prevent cell death EMBO Rep. 5 2004 213 218
304. L.C. Tan, W.P. Koh, J.M. Yuan, R. Wang, W.L. Au, and J.H. Tan Differential effects of black versus green tea on risk of Parkinson's disease in the Singapore Chinese Health Study Am. J. Epidemiol. 167 2008 553 560
305. K. Tanaka, Y. Miyake, W. Fukushima, S. Sasaki, C. Kiyohara, and Y. Tsuboi Intake of Japanese and Chinese teas reduces risk of Parkinson's disease Parkinsonism Relat. Disord. 8 2011 9
306. W.G. Tatton, R. Chalmers-Redman, D. Brown, and N. Tatton Apoptosis in Parkinson's disease: signals for neuronal degradation Ann. Neurol. 53 Suppl 3 2003 S61 S70 discussion S70-72-S61-70; discussion S70-72
307. M. Tenopoulou, T. Kurz, P.T. Doulias, D. Galaris, and U.T. Brunk Does the calcein-AM method assay the total cellular 'labile iron pool' or only a fraction of it? Biochem. J. 403 2007 261 266
308. A. Terman, T. Kurz, B. Gustafsson, and U.T. Brunk Lysosomal labilization IUBMB Life 58 2006 531 539
309. M. Terzioglu, and D. Galter Parkinson's disease: genetic versus toxin-induced rodent models FEBS J. 275 2008 1384 1391
310. S. Therade-Matharan, E. Laemmel, S. Carpentier, Y. Obata, T. Levade, and J. Duranteau Reactive oxygen species production by mitochondria in endothelial cells exposed to reoxygenation after hypoxia and glucose depletion is mediated by ceramide Am. J. Physiol. Regul. Integr. Comp. Physiol. 289 2005 R1756 R1762
311. K.J. Thompson, S. Shoham, and J.R. Connor Iron and neurodegenerative disorders Brain Res. Bull. 55 2001 155 164
312. M. Toft, L. Pielsticker, O.A. Ross, J.O. Aasly, and M.J. Farrer Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population Neurology 66 2006 415 417
313. J.F. Turrens Mitochondrial formation of reactive oxygen species J. Physiol. 552 2003 335 344
314. B. Uttara, A.V. Singh, P. Zamboni, and R.T. Mahajan Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options Curr. Neuropharmacol. 7 2009 65 74
315. E.M. Valente, P.M. Abou-Sleiman, V. Caputo, M.M.K. Muqit, K. Harvey, and S. Gispert Hereditary early-onset Parkinson's disease caused by mutations in PINK1 Science (New York, N.Y.) 304 2004 1158 1160
316. C.J. Van der Schyf, S. Gal, W.J. Geldenhuys, and M.B.H. Youdim Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases Expert Opin. Investig. Drugs 15 2006 873 886
317. E. van Nimwegen, J.P. Crutchfield, and M. Huynen Neutral evolution of mutational robustness Proc. Natl. Acad. Sci. USA 96 1999 9716 9720
318. K. Vekrellis, H.J. Rideout, and L. Stefanis Neurobiology of alpha-synuclein Mol. Neurobiol. 30 2004 1 21
319. M. Vila, and C. Perier Molecular pathways of programmed cell death in experimental Parkinson's disease Parkinsonism Relat. Disord. 14 Suppl 2 2008 S176 S179
320. M. Vila, D. Ramonet, and C. Perier Mitochondrial alterations in Parkinson's disease: new clues J. Neurochem. 107 2008 317 328
321. G. von Dassow, E. Meir, E.M. Munro, and G.M. Odell The segment polarity network is a robust developmental module Nature 406 2000 188 192
322. M. Vos, G. Esposito, J.N. Edirisinghe, S. Vilain, D.M. Haddad, and J.R. Slabbaert Vitamin K2 is a mitochondrial electron carrier that rescues pink1 deficiency Science 336 2012 1306 1310
323. J. Waak, S.S. Weber, K. Görner, C. Schall, H. Ichijo, and T. Stehle Oxidizable residues mediating protein stability and cytoprotective interaction of DJ-1 with apoptosis signal-regulating kinase 1 J. Biol. Chem. 284 2009 14245 14257
324. H. Wada, T. Yasuda, I. Miura, K. Watabe, C. Sawa, and H. Kamijuku Establishment of an improved mouse model for infantile neuroaxonal dystrophy that shows early disease onset and bears a point mutation in Pla2g6 Am. J. Pathol. 175 2009 2257 2263
325. A. Wagner Robustness, evolvability, and neutrality FEBS Lett. 579 2005 1772 1778
326. K. Wakabayashi, F. Mori, K. Tanji, S. Orimo, and H. Takahashi Involvement of the peripheral nervous system in synucleinopathies, tauopathies and other neurodegenerative proteinopathies of the brain Acta Neuropathol. 120 2010 1 12
327. U. Walter, M. Wittstock, R. Benecke, and D. Dressler Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease J. Neural Transm. 109 2002 191 196
328. C. Wang, H.S. Ko, B. Thomas, F. Tsang, K.C. Chew, and S.P. Tay Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function Hum. Mol. Genet. 14 2005 3885 3897
329. J. Wang, H. Xu, H. Jiang, X. Du, P. Sun, and J. Xie Neurorescue effect of rosmarinic acid on 6-hydroxydopamine-lesioned nigral dopamine neurons in rat model of Parkinson's disease J. Mol. Neurosci. 47 2012 113 119
330. R.J. Ward, D.T. Dexter, and R.R. Crichton Chelating agents for neurodegenerative diseases Curr. Med. Chem. 19 2012 2760 2772
331. P. Wardman, and L.P. Candeias Fenton chemistry: an introduction Radiat. Res. 145 1996 523 531
332. O. Weinreb, S. Mandel, T. Amit, and M.B. Youdim Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases J. Nutr. Biochem. 15 2004 506 516
333. O. Weinreb, S. Mandel, O. Bar-Am, M. Yogev-Falach, Y. Avramovich-Tirosh, and T. Amit Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs Neurotherapeutics 6 2009 163 174
334. J. Weisberger, F. Emmons, and W. Gorczyca Cytochemical diagnosis of Gaucher's disease by iron stain Br. J. Haematol. 124 2004 696-696
335. A.B. West, D.J. Moore, S. Biskup, A. Bugayenko, W.W. Smith, and C.A. Ross Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity Proc. Natl. Acad. Sci. USA 102 2005 16842 16847
336. M. Whitnall, and D.R. Richardson Iron: a new target for pharmacological intervention in neurodegenerative diseases Semin. Pediatr. Neurol. 13 2006 186 197
337. K.F. Winklhofer, I.H. Henn, P.C. Kay-Jackson, U. Heller, and J. Tatzelt Inactivation of parkin by oxidative stress and C-terminal truncations: a protective role of molecular chaperones J. Biol. Chem. 278 2003 47199 47208
338. K.F. Winklhofer The parkin protein as a therapeutic target in Parkinson's disease Exp. Opin. Ther. Targets 11 2007 1543 1552
339. K.F. Winklhofer, and C. Haass Mitochondrial dysfunction in Parkinson's disease Biochim. Biophys. Acta 1802 2010 29 44
340. E.S. Wong, J.M. Tan, C. Wang, Z. Zhang, S.P. Tay, and N. Zaiden Relative sensitivity of parkin and other cysteine-containing enzymes to stress-induced solubility alterations J. Biol. Chem. 282 2007 12310 12318
341. A. Wood-Kaczmar, S. Gandhi, Z. Yao, A.Y. Abramov, A.S.Y. Abramov, and E.A. Miljan PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons PLoS ONE 3 2008 e2455 e2456
342. Y. Wu, X. Li, W. Xie, J. Jankovic, W. Le, and T. Pan Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1alpha and induction of autophagy in SH-SY5Y cells Neurochem. Int. 2010
343. Y. Xia, T. Saitoh, K. Ueda, S. Tanaka, X. Chen, and M. Hashimoto Characterization of the human alpha-synuclein gene: genomic structure, transcription start site, promoter region and polymorphisms J. Alzheimers Dis. 3 2001 485 494
344. L. Xie, S.L. Kinnings, and P.E. Bourne Novel computational approaches to polypharmacology as a means to define responses to individual drugs Annu. Rev. Pharmacol. Toxicol. 52 2012 361 379
345. J. Xu, N. Zhong, H. Wang, J.E. Elias, C.Y. Kim, and I. Woldman The Parkinson's disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis Hum. Mol. Genet. 14 2005 1231 1241
346. J. Xu, N. Zhong, H. Wang, J.E. Elias, C.Y. Kim, and I. Woldman The Parkinson's disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis Hum. Mol. Genet. 14 2005 1231 1241
347. Q. Xu, A.G. Kanthasamy, and M.B. Reddy Neuroprotective effect of the natural iron chelator, phytic acid in a cell culture model of Parkinson's disease Toxicology 245 2008 101 108
348. T.A. Yacoubian, and D.G. Standaert Targets for neuroprotection in Parkinson's disease Biochim. Biophys. Acta 1792 2009 676 687
349. J. Yang, B. Benyamin, B.P. McEvoy, S. Gordon, A.K. Henders, and D.R. Nyholt Common SNPs explain a large proportion of the heritability for human height Nat. Genet. 42 2010 565 569
350. Y. Yang, Y. Ouyang, L. Yang, M.F. Beal, A. McQuibban, and H. Vogel Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery Proc. Natl. Acad. Sci. USA 105 2008 7070 7075
351. D. Yao, Z. Gu, T. Nakamura, Z.Q. Shi, Y. Ma, and B. Gaston Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity Proc. Natl. Acad. Sci. USA 101 2004 10810 10814
352. T. Yasuda, and H. Mochizuki The regulatory role of alpha-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson's disease Apoptosis 15 2010 1312 1321
353. T. Yokota, K. Sugawara, K. Ito, R. Takahashi, H. Ariga, and H. Mizusawa Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition Biochem. Biophys. Res. Commun. 312 2003 1342 1348
354. M.B. Youdim, D. Ben-Shachar, and P. Riederer Iron in brain function and dysfunction with emphasis on Parkinson's disease Eur. Neurol. 31 Suppl 1 1991 34 40
355. Z. Yu, H.L. Persson, J.W. Eaton, and U.T. Brunk Intralysosomal iron: a major determinant of oxidant-induced cell death Free Radic. Biol. Med. 34 2003 1243 1252
356. M. Zarate-Lagunes, W.J. Gu, V. Blanchard, C. Francois, M.P. Muriel, and A. Mouatt-Prigent Parkin immunoreactivity in the brain of human and non-human primates: an immunohistochemical analysis in normal conditions and in Parkinsonian syndromes J. Comp. Neurol. 432 2001 184 196
357. V. Zbarsky, K.P. Datla, S. Parkar, D.K. Rai, O.I. Aruoma, and D.T. Dexter Neuroprotective properties of the natural phenolic antioxidants curcumin and
358. L. Zecca, M.B.H. Youdim, P. Riederer, J.R. Connor, and R.R. Crichton Iron, brain ageing and neurodegenerative disorders Nat. Rev. Neurosci. 5 2004 863 873
359. J. Zhang, Y. Zhang, J. Wang, P. Cai, C. Luo, and Z. Qian Characterizing iron deposition in Parkinson's disease using susceptibility-weighted imaging: an in vivo MR study Brain Res. Mol. Brain Res. 1330 2010 124 130
360. X. Zhang, W. Xie, S. Qu, T. Pan, X. Wang, and W. Le Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration Biochem. Biophys. Res. Commun. 333 2005 544 549
361. Z. Zhang, K. Zhang, X. Du, and Y. Li Neuroprotection of desferrioxamine in lipopolysaccharide-induced nigrostriatal dopamine neuron degeneration Mol. Med. Rep. 5 2012 562 566
362. X.M. Zhao, M. Iskar, G. Zeller, M. Kuhn, V. van Noort, and P. Bork Prediction of drug combinations by integrating molecular and pharmacological data PLoS Comput. Biol. 7 2011 e1002323
363. W. Zhou, M. Zhu, M.A. Wilson, G.A. Petsko, and A.L. Fink The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein J. Mol. Biol. 356 2006 1036 1048
364. G. Zhu, X. Wang, Y. Chen, S. Yang, H. Cheng, and N. Wang Puerarin protects dopaminergic neurons against 6-hydroxydopamine neurotoxicity via inhibiting apoptosis and upregulating glial cell line-derived neurotrophic factor in a rat model of Parkinson's disease Planta Med. 76 2010 1820 1826
365. G.R. Zimmermann, J. Lehar, and C.T. Keith Multi-target therapeutics: when the whole is greater than the sum of the parts Drug Discovery Today 12 2007 34 42
366. A. Zimprich, S. Biskup, P. Leitner, P. Lichtner, M. Farrer, and S. Lincoln Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology Neuron 44 2004 601 607